乌鸦传媒

Evoque device helped outcomes in severe tricuspid regurgitation, with some safety caveats

Anti-mineralocorticoid agent reduced albuminuria, but not eGFR-based kidney outcome

Effectiveness of this personalized approach now under investigation

Panelists acknowledge difficulty generating stronger data in ultra-rare disease

Agency appears unswayed by mitochondria-targeting drug for rare cardioskeletal disease

Benefit in symptoms, functional outcomes remains to be seen for HU6

Cardiac myosin inhibitor linked to improvements in biomarkers in small study

Benefit of the nonsteroidal MRA otherwise consistent across FINEARTS-HF

Study lays out common gaps in evidence both before and after approval

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

Randomized trial "highly encouraging" for making patients feel and function better

Either choice is "acceptable" based on randomized study

ACE-PROTAVI trial tested upfront vs selective use of heparin reversal agent